{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:49:30Z","timestamp":1779148170328,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The objective of this study was to explore the safety and clinical effects of amisulpride in children and adolescents with psychiatric disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This case series included six patients, aged 11 to 19 years, diagnosed with affective disorder, autism, anxiety, psychosis, and obsessive-compulsive disorder, and treated with amisulpride at doses ranging from 100 to 400 mg per day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Amisulpride appeared to reduce psychotic and behavioral symptoms. Observed side effects included increased appetite, weight gain, sedation, and mild extrapyramidal symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Amisulpride may have promise for study and future use in children and adolescents with psychiatric disorders and severe symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2024.0139","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:19:22Z","timestamp":1739794762000},"page":"312-315","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["The Safety and Clinical Effects of Amisulpride in Children and Adolescents with Psychiatric Disorders: A Case Series"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-889X","authenticated-orcid":false,"given":"Osman","family":"\u00d6zdemir","sequence":"first","affiliation":[{"name":"Associate Professor of Psychiatry, Independent Researcher, Van, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0153"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161140-00014"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1993.3.145"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.03.028"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.12740\/PP\/OnlineFirst\/109129"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S6226"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30252-9"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125001083"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1721-6"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181bf613e"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.08.026"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.130510"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.512"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.07.001"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(99)00075-X"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1714029"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1202"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001529"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-009-0009-8"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2024.0139","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2024.0139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:57:14Z","timestamp":1777388234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2024.0139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1089\/cap.2024.0139"],"URL":"https:\/\/doi.org\/10.1089\/cap.2024.0139","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]}}}